Shanghai Kaibao Pharmaceutical Strategic Asset Allocation Index
Shanghai Kaibao Pharmaceutical strategic asset allocation index. Shanghai Kaibao Pharmaceutical (300039) has a Strategic Asset Allocation Index of 7.7% as of September 2023. Strategic assets (PP&E of CN¥294.75 Million plus long-term investments of CN¥-) total CN¥294.75 Million, measured against net assets of CN¥3.82 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Shanghai Kaibao Pharmaceutical (300039) net asset quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Shanghai Kaibao Pharmaceutical (2006–2021)
Strategic asset allocation index of Shanghai Kaibao Pharmaceutical from 2006 to 2021. This chart shows how Shanghai Kaibao Pharmaceutical's Strategic Asset Allocation Index has evolved across 16 annual periods from 2006 to 2021. As of September 2023, the index stands at 7.7%, representing strategic assets of CN¥294.75 Million against net assets of CN¥3.82 Billion CNY. Check Shanghai Kaibao Pharmaceutical tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Shanghai Kaibao Pharmaceutical Strategic Asset Allocation Index by Year (2006–2021)
Shanghai Kaibao Pharmaceutical strategic asset allocation index by year from 2006 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Shanghai Kaibao Pharmaceutical from 2006 to 2021, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300039 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 10.1% | CN¥307.78 Million | CN¥307.78 Million | CN¥- | CN¥3.04 Billion | ▼ -1.4 pp |
| 2020 | 11.5% | CN¥295.87 Million | CN¥295.87 Million | CN¥- | CN¥2.58 Billion | ▼ -1.2 pp |
| 2019 | 12.7% | CN¥326.81 Million | CN¥326.81 Million | CN¥- | CN¥2.57 Billion | ▼ -8.8 pp |
| 2018 | 21.6% | CN¥535.72 Million | CN¥353.29 Million | CN¥182.44 Million | CN¥2.49 Billion | ▼ -0.8 pp |
| 2017 | 22.4% | CN¥528.73 Million | CN¥374.39 Million | CN¥154.34 Million | CN¥2.37 Billion | ▼ -2.8 pp |
| 2016 | 25.2% | CN¥553.67 Million | CN¥372.85 Million | CN¥180.82 Million | CN¥2.20 Billion | ▲ +2.4 pp |
| 2015 | 22.8% | CN¥456.89 Million | CN¥401.09 Million | CN¥55.80 Million | CN¥2.01 Billion | ▲ +4.4 pp |
| 2014 | 18.4% | CN¥347.19 Million | CN¥347.19 Million | CN¥- | CN¥1.88 Billion | ▼ -3.7 pp |
| 2013 | 22.1% | CN¥355.65 Million | CN¥355.65 Million | CN¥- | CN¥1.61 Billion | ▲ +4.3 pp |
| 2012 | 17.8% | CN¥252.52 Million | CN¥252.52 Million | CN¥- | CN¥1.42 Billion | ▼ -1.0 pp |
| 2011 | 18.8% | CN¥251.22 Million | CN¥251.22 Million | CN¥- | CN¥1.33 Billion | ▲ +1.5 pp |
| 2010 | 17.4% | CN¥214.90 Million | CN¥214.90 Million | CN¥- | CN¥1.24 Billion | ▲ +4.4 pp |
| 2009 | 13.0% | CN¥148.44 Million | CN¥148.44 Million | CN¥- | CN¥1.15 Billion | ▼ -14.2 pp |
| 2008 | 27.1% | CN¥34.45 Million | CN¥34.45 Million | CN¥- | CN¥126.92 Million | ▼ -13.6 pp |
| 2007 | 40.7% | CN¥31.32 Million | CN¥31.32 Million | CN¥- | CN¥76.96 Million | ▼ -41.3 pp |
| 2006 | 82.0% | CN¥30.55 Million | CN¥30.55 Million | CN¥- | CN¥37.24 Million | — |